Inclusion Criteria:

- Male or female patients, aged ≥ 18 years

- Unequivocal diagnosis of primary HCC (confirmed by biopsy/histology or EASL criteria)

- Tumour characteristics as follows:

- Not more than 5 lesions

- If single, maximal diameter ≤ 10 cm

- If multiple, sum of maximal diameters ≤ 15 cm

- Lesions satellite to primary tumour of less than 1 cm in maximal diameter are
not included

- At least one quantifiable lesion on hepatic MRI

- Preserved liver function, corresponding to Child-Pugh class ≤ B-7

- ECOG performance status ≤ 2

- Life expectancy ≥ 12 weeks

- Female patients of childbearing potential must have a negative pregnancy test prior
to inclusion in the trial and male and female patients must agree to use an effective
contraceptive method for the duration of the trial.

- Willing and able to provide written informed consent

Exclusion Criteria:

- Patients expected to undergo surgery (resection or transplantation) within the
24-week period after randomisation.

- Ascites, which is detectable on physical examination or clinically symptomatic (but
patients having ascites discovered by imaging only should not be excluded).

- Serum transaminases > 5 x ULN

- Lung shunt > 20%

- Extrahepatic disease

- Moderate to severe portal hypertension, as evidenced by any of the following criteria
(occurring in spite of using common criteria for prophylactic treatment and therapy):

- History of variceal haemorrhage in past 2 years

- History of hepatic encephalopathy

- Platelets < 50.000 /ml

- WBC < 3.000 / ml

- Previous TIPSS procedure

- Portal vein occlusion or hepatofugal flow.

- Impaired liver function

- Total serum bilirubin > 2.0 mg / dL

- Serum albumin < 3.0 g /dl

- creatinine > 2 mg / dL

- Chemotherapy or other experimental therapy within preceding 4 weeks

- Previous TAE / TACE

- Previous radiation therapy to liver or lungs

- Contraindications for angiography (severe peripheral vascular disease or
uncorrectable bleeding diathesis)

- Anatomical variants apparent on 99mTc-MAA scan precluding safe administration of RE

- Any decompensated concomitant disease

- Female patients who are pregnant, breast-feeding, or pre-menopausal and not
practising efficient contraceptive method (hormonal contraceptive, intra-uterine
device)